............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
New Leaf Venture Partners Expands
Leadership Team, Naming Liam Ratcliffe, M.D., Ph.D., as Venture
Partner
NEW YORK--(BUSINESS WIRE)—Sept. 2, 2008 -- New Leaf Venture
Partners (NLV Partners) announced today the appointment of Liam
Ratcliffe, M.D., Ph.D., as venture partner. Dr. Ratcliffe
recently served as Senior Vice President and Global Head of
Clinical Research and Development for Pfizer. Dr. Ratcliffe's
appointment is effective immediately, and he will be based in
NLV Partners' New York office.
"During his 12 year tenure at Pfizer, Liam worked at the
interfaces between drug discovery, pre-clinical development and
experimental medicine," stated Philippe Chambon, M.D., Ph.D.,
Managing Director at NLV Partners. "These experiences have given
him a deep understanding of the opportunities and risks along
the clinical development axis and across therapeutic fields.
This background will be a great asset as Liam works with
existing and potential portfolio companies in helping them
de-risk their most critical pipeline projects."
Dr. Ratcliffe commented, "I am pleased to join NLV Partners,
which has a leading franchise in healthcare technologies. My
pharmaceutical background complements the experience of the
seasoned NLV team and provides another perspective for young
companies assessing their allocation of resources and business
development strategies."
Dr. Ratcliffe most recently served as senior vice president and
development head for Pfizer Neuroscience, as well as worldwide
head of Clinical Research and Development. Additional positions
at Pfizer included vice president of Exploratory Development for
the Mid West region, and head of Experimental Medicine at
Pfizer’s Sandwich, UK Laboratories.
As head of Neurosciences, Dr. Ratcliffe was responsible for the
development of several successful late-stage projects and
marketed products, including PD 332, 334, Lyrica, Chantix and
Geodon. In previous roles, he gained extensive experience in
early drug development and translational research across
multiple therapeutic areas, including inflammation, pain,
cardiovascular disease, infectious diseases and genitor-urinary
medicine.
Dr. Ratcliffe began his career in the pharmaceutical industry in
a medical marketing role at Roche in South Africa. He received
his M.D. degree and Ph.D. degree in immunology from the
University of Cape Town and his MBA degree from the University
of Michigan. Dr. Ratcliffe completed his internal medicine
training and fellowship in Immunology at Groote Schuur Hospital
and additional teaching hospitals in Cape Town, South Africa.
About NLV Partners
NLV Partners is a life science-dedicated venture capital firm
with offices in Menlo Park and New York. Founded by an
experienced team of venture capitalists with deep healthcare
industry experience, NLV Partners invests primarily in companies
focused on clinical-stage biopharmaceutical products,
early-stage medical devices, and molecular diagnostics. NLV
Partners manages over $1.3 billion of assets, including NLV-I,
NLV-II and the healthcare technology portfolio of Sprout Group.
For further information, visit the NLV Partners website at
www.nlvpartners.com. |